Summary
There is conflicting data in the literature as to whether subsensitivity of in-vivo β2-adrenoceptor (β2-AR) responses in patients with asthma is due to an endogenous defect of β2-AR or an effect of exogenous β2-agonist therapy. The purpose of the study was to compare in-vitro parameters of lymphocyte β2-AR function in eight age and sex matched normal [FEV1, 98 (2) % predicted] volunteers and asthmatic [FEV1, 60 (5) % predicted] subjects. The asthmatic group were washed out for 4 weeks by substituting inhaled β2-agonist therapy with ipratropium bromide, in order to exclude possible exogenous effects of β2-agonist exposure. Receptor binding affinity (Kd) and density (Bmax) were evaluated using (-)125I-iodocyanopindolol and maximal cAMP response (Emax) was assayed following stimulation with isoprenaline (10−4M).
No significant differences were found between the normal and asthmatic group for Kd (pmol·l−1): 9.65 vs 10.2, Bmax (fmol/106 cells): 1.9 vs 1.6, or Emax (pmol/106 cells): 4.24 vs 4.85.
Thus, parameters of β2-AR function are unaltered in asthmatic patients who have not been exposed to β2-agonists, suggesting that asthma is not associated with an endogenous defect of β2-AR.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brodde OE, Howe U, Egerszegi S, Konietzko N, Michel MC (1988) Effect of prednisolone and ketotifen on β2-adrenoceptors in asthmatic patients receiving β2-bronchodilators. Eur J Clin Pharmacol 34: 145–150
Brooks SM, McGowan K, Bernstein IL, Altenau P, Peagler J (1979) Relationship between numbers of beta adrenergic receptors in lymphocytes and disease severity in asthma. J Allergy Clin Immunol 63: 401–406
Brown PH, Blundell G, Greening AP, Crompton GK (1990) Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? Thorax 45: 736–739
Brown PH, Blundell G, Greening AP, Crompton GK (1991) Hypothalamic-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids. Resp Med 85: 501–510
Connolly ME, Greenacre JK (1976) The lymphocyte β-adrenoceptor in normal subjects and patients with bronchial asthma. J Clin Invest 58: 1307–1316
Connolly MJ, Crowley JJ, Nielson CP, Charan NB, Vestal RE (1992) Relationships between non-specific bronchial responsiveness to methacholine and peripheral mononuclear leukocyte beta-adrenergic receptor function in young drug-naive subjects. Am Rev Respir Dis 146: 592–597
Ebden P, Jenkins A, Houston G, Davies BH (1986) Comparison of two high dose corticosteroid aerosol treatments, beclomethasone diproprionate (1500 μg/day) and budesonide (1600 μg/day) for chronic asthma. Thorax 41: 869–874
Hauck RW, Bohm M, Gengebach MS, Sunder-Plassmann L, Fruhmann G, et al (1990) β2-adrenoceptors in human lung and peripheral mononuclear leukocytes of untreated and terbutaline-treated patients. Chest 9: 376–381
Johansson SA, Anderson KE, Brattsand R, Gruvstad E, Hedner P (1982) Topical and systemic glucocorticoid potencies of budesonide and beclomethasone diproprionate in man. Eur J Clin Pharmacol 22: 523–529
Kariman K (1980) β-adrenergic receptor binding in lymphocytes from patients with asthma. Lung 158: 41–51
Lipworth BJ, Clark RA, Dhillon DP, McDevitt DG (1990) Subsensitivity of β-adrenoceptor responses in asthmatic patients taking regular low-dose inhaled salbutamol. Eur J Clin Pharmacol 38: 203–205
Lipworth BJ, Struthers AD, McDevitt DG (1989) Tachyphylaxis to systemic but not airways responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis 140: 586–592
Logsdon PJ, Middleton E, Coffey RG (1972) Stimulation of leukocyte adenyl cyclase by hydrocortisone and isoproterenol in asthmatic and non asthmatic subjects. J Allergy Clin Immunol 50: 45–56
Molema J, Lammers JWJ, van Herwaarden CLA, Folgering HTM (1988) Effects of inhaled beclomethasone depropionate on β2-receptor function in the airways and adrenal responsiveness in bronchial asthma. Eur J Clin Pharmacol 34: 577–583
Morris HG, Rusnak SA, Barzens K (1977) Leukocyte cyclic adenosine monophosphate in asthmatic children: effects of adrenergic therapy. Clin Pharmacol Ther 22: 352–357
Parker CW, Smith JW (1973) Alterations in cyclic adenosine monophosphate metabolism in human bronchial asthma. I. Leukocyte responsiveness to β2-adrenergic agents. J Clin Invest 52: 48–59
Parker CW, Huber MG, Baumann ML (1973) Alterations in cyclic AMP metabolism in human bronchial asthma. III. Leukocyte and lymphocyte response to steroids. J Clin Invest 52: 1342–1348
Rahman ARA, McDevitt DG, Struthers AD, Lipworth BJ (1992) Sex-differences in hypokalaemic and electrocardiographic effects of inhaled terbutaline. Thorax 47: 1056–1059
Sano Y, Watt G, Townley RG (1983) Decreased mononuclear cell beta-adrenergic receptors in bronchial asthma: parallel studies of lymphocyte and granulocyte desensitization. J Allerg Clin Immunol 72: 495–503
Szentivanyi A (1968) The β-adrenergic theory of the atopic abnormality in bronchial asthma. J Allergy 42: 203–232
Whicker SD, Armour CL, Black JL (1988) Responsiveness of bronchial smooth muscle from asthmatic patients to relaxant and contractile agents. Pulm Pharmacol 1: 25–31
Wolfe RN, Hui KK, Connolly MD, Tashkin DP, Fisher HK (1982) A study of beta-adrenergic and prostaglandin receptors in patients with aspirin-induced bronchospasm. J Allerg Clin Immunol 69: 46–50
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Newnham, D.M., Coutie, W.J.R., McFarlane, L.C. et al. Comparison of parameters of in vitro lymphocyte β2-adrenoceptor function in normal and asthmatic subjects. Eur J Clin Pharmacol 45, 535–538 (1993). https://doi.org/10.1007/BF00315310
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315310